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Abstract
Background: Guidelines recommend moderate to high-intensity statins and antithrombotic agents 
in patients with atherosclerotic cardiovascular disease (ASCVD). However, guideline-directed medical 
therapy (GDMT) remains suboptimal.
Methods: In this quality initiative, best practice alerts (BPA) in the electronic health record (EHR) 
were utilized to alert providers to prescribe to GDMT upon hospital discharge in ASCVD patients. Rates 
of GDMT were compared for 5 months pre- and post-BPA implementation. Multivariable regression 
was used to identify predictors of GDMT.
Results: In 5985 pre- and 5568 post-BPA patients, the average age was 69.1 ± 12.8 years and 58.5% 
were male. There was a 4.0% increase in statin use from 67.3% to 71.3% and a 3.1% increase in an-
tithrombotic use from 75.3% to 78.4% in the post-BPA cohort.  
Conclusions: This simple EHR-based initiative was associated with a modest increase in ASCVD 
patients being discharged on GDMT. Leveraging clinical decision support tools provides an opportunity 
to influence provider behavior and improve care for ASCVD patients, and warrants further investiga-
tion. (Cardiol J)
Key words: cardiovascular disease, secondary prevention, guideline-directed medical 
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Introduction
Secondary prevention guidelines from major 
medical societies in the United States emphasize 
at least moderate to high-intensity statins, anti-
platelet agents, and lifestyle change in patients 
with established atherosclerotic cardiovascular 
disease (ASCVD) (AHA/ACC, AACE, NLA, IAS) 
[1–5] based on an abundance of data demonstrat-
ing both morbidity and mortality benefit [6, 7]. 
However, patient medical regimens and risk factors 
remain suboptimal in clinical practice [8–10], and 
even in large randomized controlled trials where 
emphasis is placed on optimal medical therapy 
[11]. Inpatient interventions to improve utilization 
and adherence to secondary prevention strategies 
may improve outcomes. At our own institution, we 
previously reported improvements in guideline-
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directed medication therapy (GDMT) associated 
with inpatient preventive cardiology consultations, 
and a prescription given at the time of discharge 
was associated with improved medicine regimens 
at 6-month follow-up [12]. In addition, lifestyle 
education at the time of discharge is not universal 
[13]. Patients may leave the hospital without under-
standing the potential benefit of lifestyle changes, 
which risk factors need to be improved, and how 
best to optimize their cardiovascular risk. 
Clinical decision support instruments built 
into electronic health record (EHR) systems 
provide an opportunity to improve provider adher-
ence to cardiovascular clinical practice guidelines. 
These instruments have been shown to increase 
the appropriateness of antimicrobial prescribing 
in the inpatient setting [14, 15]. Customized edu-
cational hand-outs specific to patient diagnosis at 
the time of discharge printed in the EHR after-visit 
summary can ensure that all patients receive the 
same basic information and resources for lifestyle 
improvement. Educational materials are currently 
available online from many organizations (Car-
diosmart, National Lipid Association, American 
Heart Association) and can be customized based 
on institutional guidelines.
The impact of clinical decision support and 
educational materials provided in the after-visit 
summary on utilization and adherence to cardiovas-
cular secondary prevention guidelines has not been 
established. We sought to determine the impact of 
a quality improvement initiative using clinical deci-
sion support to optimize adherence to GDMT and 
patient education at the time of hospital discharge 
in patients with established ASCVD. 
Methods
Patients
Adults age ≥ 18 years with an established 
diagnosis of ASCVD discharged from inpatient 
hospitalization, medical observation, or ambula-
tory procedures at New York University Langone 
Health from February 2016 to February 2018 were 
eligible for inclusion. A diagnosis of ASCVD was 
defined by ≥ 1 ASCVD-associated diagnoses in the 
principal problem list of the EHR. Patients were 
excluded if they expired during the hospitalization, 
were discharged to hospice, had a known allergy 
to statin therapy, or had liver enzymes that were 
greater than two-times the upper limit of normal. 
Among patients with multiple visits during the 
study timeframe, only the first eligible encounter 
was included in the primary analysis.
Clinical decision support interventions
As part of ongoing quality improvement initia-
tives at New York University Langone Health, the 
Division of Value Based Medicine championed 
a ‘discharge-centered’ secondary prevention pro-
gram to improve compliance with the medical 
center’s Clinical Practice Guidelines for patients 
with ASCVD. In collaboration with our institution’s 
Medical Center Information Technology group, we 
developed best practice alerts (BPAs) in the EHR 
to serve as real-time reminders about GDMT to 
providers caring for inpatients with ASCVD. The 
first BPA was designed as a ‘passive’ notification of 
recent hemoglobin A1c (HbA1c) and lipid results 
that included an optional one-click order to repeat 
lipid and HbA1c laboratory testing. The second 
and third BPAs were designed to interrupt the 
provider’s workflow with recommendations for 
statin and antithrombotic therapy at the time of 
discharge and included a link to prescribe appro-
priate statin and/or antithrombotic therapy. These 
alerts were targeted to selected patients with an 
ASCVD diagnosis who did not have an existing 
prescription for moderate or high-intensity statin 
or antithrombotic therapy. The BPAs allowed pro-
viders to decline statin and antithrombotic therapy 
orders and provide a rationale for this clinical deci-
sion. The BPA for statin therapy at discharge was 
not displayed for patients with documented statin 
allergies in the EHR.
Patient education intervention
To complement the decision support interven-
tion, patient educational materials were developed 
for patients with ASCVD. These materials provided 
descriptions of ASCVD diagnoses, optimal diets for 
risk reduction, physical activity recommendations, 
and patient lifestyle resources. To allow patients to 
understand their own ASCVD risk factor control, 
each form was customized with patient-specific 
values for HbA1c, blood pressure, low-density 
lipoprotein cholesterol (LDL-C), body mass index 
(BMI), smoking status, and the corresponding 
target values. Patient educational materials were 
distributed via the EHR-generated after-visit sum-
mary provided at discharge to all eligible patients 
with ASCVD.
Provider education
Once the BPAs and educational material in the 
after-visit summary were fully incorporated into 
the EHR, hospital providers (nurse practitioners, 
physician assistants, and graduate medical educa-
tion trainees) were notified about the initiative and 
www.cardiologyjournal.org 3
Anish Vani et al., Leveraging clinical support tools to improve GDMT
provided hospital ASCVD guidelines. Representa-
tives of each hospital inpatient, observation, and 
ambulatory unit received dedicated education from 
a member of the Division of Cardiology during the 
initial implementation phase.
Assessment of the quality improvement  
intervention and outcomes
The EHR-based intervention was launched on 
July 24, 2017, and the education of providers was 
conducted between June and September 2017. In 
order to evaluate the impact of the EHR-based 
intervention, data was collected over two 5-month 
periods, prior to (January 2017 to May 2017), and 
following (October 2017 to February 2018), the full 
implementation of the EHR-based intervention. 
The primary outcome of interest was the propor-
tion of ASCVD patients prescribed GDMT with 
a moderate or high-intensity statin and antithrom-
botic therapy at the time of discharge. Data regard-
ing actions in response to the interruptive BPAs 
was collected to understand provider behavior. Ad-
ditional data collected from the electronic medical 
record included patient demographics, HbA1c, total 
cholesterol, LDL, serum liver enzymes, hospital 
service, and discharge diagnosis. Preadmission and 
discharge medication lists were obtained from the 
EHR. Moderate and high-intensity statins were 
classified based on ACC/AHA definitions. Specifi-
cally, high-intensity statins included atorvastatin 
40 mg, atorvastatin 80 mg, rosuvastatin 20 mg, 
and rosuvastatin 40 mg. Moderate-intensity statins 
included atorvastatin 10 mg, atorvastatin 20 mg, 
rosuvastatin 5 mg, rosuvastatin 10 mg, pravastatin 
40 mg, simvastatin 40 mg, and lovastatin 40 mg. 
Eligible antithrombotic therapy included acetylsali-
cylic acid, clopidogrel, prasugrel, ticagrelor, vora-
paxar, as well as warfarin, rivoraxaban, dabigatran, 
apixiban, and edoxaban.
Statistical analysis 
Continuous variables were reported as means 
and standard deviations and were compared by the 
Student t-test. Categorical variables were reported 
as proportions and compared by c2 tests. Univari-
ate and multivariable regression was performed 
to identify predictors of discharge on GDMT after 
adjusting for age, sex, admission type, admitting 
service, and whether the admission occurred be-
fore or after implementation of the BPA and patient 
education intervention. Statistical significance 
was defined as two-tailed p < 0.05 for all tests. 
Statistical analysis was performed using the R 
Foundation for Statistical Computing’s R version 
3.5.0 (Vienna, Austria).
Results
Among 11,553 patients who were included in 
the analysis, the mean age was 69.1 ± 12.8 years, 
58.5% were male, and 66.2% and 74.3% were on 
a statin and antithrombotic agent on admission, 
respectively (Table 1). The pre-BPA (n = 5985) 
and post-BPA (n = 5568) cohorts were similar 
with regards to baseline characteristics; however, 
a greater proportion of patients in the post-BPA 
cohort were on a statin on admission (67.7% vs. 
64.8%, p = 0.001). Patients were primarily treated 
on a cardiology (37.9%), medicine (27.6%), or sur-
gical (20.2%) service. A majority of patients were 
treated in the outpatient setting for an ambulatory 
procedure (57.6%) or the inpatient setting (32.8%).
Comparing pre- and post-BPA implementation, 
there was a 4.0% increase in discharge statins, 
3.6% increase in high-intensity statins, and 3.1% 
increase in antithrombotic agents in the post-BPA 
cohort (p < 0.001 for all comparisons) (Fig. 1). 
There were significant increases in the rates of 
statin prescriptions at discharge among inpatients, 
patients undergoing ambulatory procedures, and 
among patients admitted to a medicine or surgi-
cal service (Fig. 2A, B). A significant increase in 
discharge antithrombotic rates among surgical pa-
tients was also observed (Fig. 2C, D). There were 
5.3% and 6.8% new antithrombotic prescriptions 
at discharge compared to admission in the pre- and 
Table 1. Baseline characteristics in the pre- and post-best practice alert implementation cohorts.







Age [years] 69.1 ± 12.8 69.2 ± 12.8 68.9 ± 12.8 0.27
Male sex 58.5% 57.7% 59.3% 0.07
Admission statin 66.2% 64.8% 67.7% 0.001
Admission antithrombotic 74.3% 73.8% 74.9% 0.18
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Figure 2. Rates of guideline-directed medical therapy on discharge by admitting service and admission type. Distribu-
tion of discharge statin pre- and post-best practice alert implementation by admission type (A) and admitting service 
(B). Distribution of discharge antithrombotic pre- and post-best practice alert implementation by admission type (C) 
and admitting service (D).
Figure 1. Rates of guideline-directed medical therapy on hospital discharge; A. Compares pre- and post-best practice 
alert implementation rates of discharge statin and antithrombotic rates; B. Compares the breakdown of moderate and 
high-intensity statin rates on discharge. 
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post-BPA cohorts, respectively (p < 0.001). There 
were 4.4% and 5.1% new statin prescriptions at 
discharge compared to admission in the pre- and 
post-BPA cohorts, respectively (p = 0.08).
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After multivariable regression, older age, male 
sex, admission post-BPA implementation, and ad-
mission to a cardiology or medicine service were 
associated with an increased odds of discharge on 
a statin or antithrombotic agent for ASCVD (Table 2).
During the course of the study, the BPA was 
activated during 1,117 discharges to prompt pro-
viders to prescribe statins and 1,067 discharges 
to prompt providers to prescribe antithrombotic 
agents. Providers dismissed the BPA over 80% 
of the time; it changed prescribing behavior in 
a minority of cases (8%). Reasons for the BPA 
being dismissed are listed in Figure 3. Clinician 
or patient preferences were leading justifications 
for failure to discharge patients on a statin. In-
creased bleeding risk was the leading justification 
for failure to discharge patients on an antithrom-
botic agent.  
Table 2. Multivariable regression for predictors of discharge statin or antithrombotic agent.
Statin prescribing  
at hospital discharge
Antithrombotic prescribing  
at hospital discharge
b (SEM) P b (SEM) P
Age [year] 0.02 (0.00) < 0.001 0.03 (0.00) < 0.001
Sex: Male (vs. Female) 0.53 (0.04) < 0.001 0.64 (0.05) < 0.001
Post-BPA implementation  
(vs. Pre-BPA implementation)
0.19 (0.04) < 0.001 0.17 (0.05) < 0.001
Patient class: Inpatient  
(vs. All other patient classes as control)
–0.05 (0.05) 0.32 0.14 (0.05) < 0.001
Service: Cardiology  
(vs. All other services as control)
0.89 (0.05) < 0.001 1.72 (0.06) < 0.001
Service: Medicine  
(vs. All other services as control)
0.35 (0.04) < 0.001 0.67 (0.05) < 0.001
*Adjusted for age, sex, admission time relative to BPA implementation (pre- or post-BPA implementation), patient class and admitting service; 
BPA — best practice alert; SEM — structural equation modeling
A B
Increased bleeding risk





















Figure 3. Reasons clinicians dismissed best practice alert recommendations; A. Statin best practice alert (BPA): 
Reasons clinicians disregarded the BPA; B. Antithrombotic BPA: Reasons clinicians disregarded the BPA; ASA — 
acetylsalicylic acid; LFT’s — liver function tests.
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Discussion
Despite the impressive cardiovascular ad-
vances of our time, limitations persist in seemingly 
simple factors such as achieving optimal medical 
therapy and the implementation of lifestyle modi-
fication to promote cardiovascular health [16]. This 
quality improvement initiative at our institution 
illustrates a straightforward, cost-effective mecha-
nism whereby medical centers with EHR capabili-
ties can modestly improve compliance with GDMT 
and provide patient-centered educational materials 
at the critical juncture of hospital discharge. This 
type of initiative may help overcome health system, 
provider and patient factors that frequently stand 
in the way of health improvement [16]. 
After implementation of our initiative, we 
observed a statistically significant, albeit modest, 
increase in provider compliance with GDMT; spe-
cifically, a 4.0% increase was identified in discharge 
prescriptions for statins, a 3.6% increase in high-in-
tensity statins and 3.1% increase in antithrombotic 
agents in the cohort post-BPA implementation. 
Moreover, significant increases in discharge statin 
rates were noted among inpatients admitted to 
a medicine or surgical service. The intervention also 
had an impact in patients undergoing ambulatory 
procedures as well, even though the window for 
medical optimization prior to discharge was brief.
Unfortunately, in this study providers dismissed 
the BPA recommendations over 80% of the time, 
and the BPA impacted prescribing behavior in only 
8% of cases. While we were able to collect broad 
information regarding the reasons that the BPA was 
dismissed by discharging providers (Fig. 3), future 
work at our institution will aim to clarify the etiologies 
of “clinician preference” and “patient preference” in 
order to identify additional interventions to improve 
compliance with GDMT in the hospital discharge 
process. It was suspected that some responses to 
the BPA may have been a result of alarm fatigue. 
The constant inundation of EHR alerts may drive 
providers to bypass the alerts in order to complete the 
remainder of the workflow for patient care. Institu-
tions may need to prioritize which alerts are essential 
and limit others that may impede care.
While more limited in scope and duration, our 
institution’s quality initiative shares similarities 
with the impressive Intermountain Health Sys-
tem’s “Hospital-Based Discharge Medication 
Program” for cardiovascular disease implemented 
in the early 2000’s at all ten Intermountain hos-
pitals. These investigators were able to achieve 
upwards of 90% compliance with GDMT and saw 
significant decreases in the relative risk for death 
at 1 year as well as readmission at 30 days [17]. 
One key difference that might account for the 
high compliance and success of the Intermoun-
tain program was that discharge-planning nurses 
were required to directly contact an attending or 
resident physician if an appropriate medication 
was not prescribed — essentially creating a ‘hard 
stop’ during the discharge process until the medica-
tion was prescribed or a specific contraindication 
was documented.  Future iterations of our quality 
initiative could include a similar hard stop in the 
discharge process to more effectively influence 
discharge providers’ prescribing behaviors.
The present study is limited by its obser-
vational, non-randomized, single-center design. 
Although the overall effect of the intervention was 
small and must be balanced against other competing 
factors such as alarm fatigue and provider frustra-
tion, this study demonstrates the feasibility of 
a simple intervention to increase provider adherence 
to prescribe GDMT. Refinement in patient selection 
or the addition of potential ‘hard stops’ for providers 
in the discharge process (‘obstructive intervention’) 
may further enhance the impact of BPAs. Addition-
ally, a relatively short duration of time for analysis 
was utilized; further trends in prescribing behavior 
and compliance to GDMT might be clarified with 
a longer period of follow-up post-BPA implementa-
tion. To better ascertain the downstream effects 
of our simple EHR-based initiative, we intend to 
investigate changes in future hospital cardiovascular 
readmission rates. Lastly, although we were able to 
successfully implement a mechanism for discharging 
patients with educational materials and resources, 
we were unable to directly link improvements in 
lifestyle, cardiovascular risk factors or medication 
use to these educational materials.
Conclusions
In summary, with a simple, cost-effective 
EHR-based quality initiative we were able to 
demonstrate a modest increase in compliance 
with GDMT for ASCVD patients and improve the 
quality of care delivered at hospital discharge at 
a large academic medical center. As demonstrated 
in the current study, quality improvement programs 
are feasible and may be easily implemented to sig-
nificantly increase adherence to GDMT. Improve-
ments in GDMT adherence may pave the way for 
reductions in cardiovascular readmission rates and 
mortality, thereby reducing the tremendous burden 
of cardiovascular disease [18, 19]. 
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